D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. Data were presented at the 2013 European Cancer Conference in Amsterdam.
AP26113, a second-generation ALK inhibitor, has the broadest spectrum of activity of any of the second-generation inhibitors in terms of the known resistance mutations, Camidge says.
AP26113 showed a 61% response rate in patients who are resistant to crizotinib, including one patient who was intolerant to crizotinib. Most interestingly, Camidge says, the study showed the agent had activity in brain metastases. The study showed that 8 out of 10 patients with active brain metastases were experiencing shrinkage following treatment with AP26113.
Camidge says the duration of benefit is not yet mature, but long-term central nervous system (CNS) responses were observed.
<<< View more from the 2013 European Cancer Congress